Abstract: Retinal arachidonic acid (ARA) levels in form-deprived eyes decline in guinea pigs. As prostaglandin F2a (PGF2a) is an ARA metabolite and endogenous agonist of prostaglandin F receptor (FP), we have been suggested that down-regulation of PGF2a-FP receptor signalling pathway contributes to myopia onset. To test this hypothesis, this study determines whether: (i) retinal PGF2a levels decline during the development of form deprivation myopia (FDM) in guinea pigs; (ii) FP receptor agonism and antagonism alter emmetropization and myopia development. Pigmented guinea pigs were randomly assigned to normal vision and form-deprived groups. Ultraperformance liquid chromatography coupled with a mass spectrometer (UPLC-MS) measured retinal PGF2a levels 2 weeks after form deprivation (FD). The selective FP agonist, latanoprost acid (LAT) and its corresponding antagonist, AL8810, were peribulbarly injected into each group. An eccentric infrared photorefractor (EIR) monitored refraction. A-scan ultrasonography measured axial elongation (AL) and vitreous chamber depth (VCD). Tonometry measured the intraocular pressure (IOP). Retinal PGF2a levels declined in form-deprived eyes compared to those in normal eyes. Neither LAT nor AL8810 affected IOP with or without FD. On the other hand, after 4 weeks of daily 0.5 lg AL8810 treatment, a myopia of À1.99 AE 0.34 dioptre (D) developed, but LAT had no effect on emmetropization in a normal visual environment. Nevertheless, daily 30 lg LAT treatment for 4 weeks inhibited FDM development by 41% (vehicle control: À8.39 AE 0.45 D; LAT: À4.95 AE 0.39 D; two-way ANOVA with repeated measures, p < 0.05). Down-regulation of PGF2a-FP receptor signalling pathway may contribute to myopia onset as retinal PGF2a declined in myopic eyes and antagonism of FP receptor by AL8810 induced a myopic shift in normal vision environment. Meanwhile, up-regulation of this pathway by LAT inhibited FDM development. However, the mechanism underlying LAT-induced FDM inhibition needs further clarification. This uncertainty exists because its inhibition of FDM suggests that LAT strengthens the scleral framework which reduces axial elongation. On the other hand, its IOP-lowering effect is attributed to thinning and weakening the scleral framework in glaucoma treatment.
Emmetropia is characterized by a match between the ocular refractive power and its axial length resulting in distant images being focused at the retinal photoreceptor layer in the absence of accommodation. Myopia is a refractive error characterized by inappropriate ocular elongation and scleral remodelling resulting in nearsightedness and even blindness in severe cases. This condition is already the most prevalent refractive error in the world and increases in its occurrence are reaching epidemic proportions in east Asian countries [1] . Despite significant advances in the treatment of this sight compromising condition, therapeutic management can be improved by identifying the receptor-linked cell signalling pathways affecting its development [2] .
An experimental animal model of myopia extensively used to evaluate drug effects on its progression is referred to as form deprivation myopia (FDM). It entails imposing visual distortion by outfitting a translucent diffuser or diffusing lens. This model has been used in a variety of animals, including chicken, primates, tree shrews, mice, and guinea pigs, to clarify cellular mechanisms underlying myopia development in humans [3] . In numerous studies employing the FDM model, both cholinergic [4] and dopaminergic [5] drugs altered myopia progression through selectively either stimulating or blocking receptor activation. Even though FP receptor expression was identified in the human eye [6, 7] , there are few reports describing its functional involvement in modulating eye growth in different visual environments. One initial study implicated possible FP receptor involvement because intravitreal injection of its endogenous agonist, PGF2a, significantly reduced axial elongation induced by form deprivation (FD) in chicks [8] .
Guinea pigs are on average 4.4 D hyperopic 2 days after birth and rapidly develop towards emmetropia at a constant rate of 12% during the first 30 days following birth [9] . We found FD induced a myopic shift in refraction from 2 to 8 weeks of age [10] . Recently, we showed that FD decreased retinal arachidonic acid (ARA) levels in a guinea pig metabolomics study [11] . Such declines are relevant because ARA can be catalysed by cyclooxygenase (COX) to produce prostaglandins including PGF2a [12] . This ARA decline in myopic retina implied that decreases in retinal PGF2a levels may occur along with down-regulation of its coupled signalling pathway. Based on the aforementioned study involving PGF2a-induced suppression of axial length extension in chicks, we have been suggested that declines in PGF2a promote myopia pathogenesis through inhibiting FP receptor activation in guinea pigs. However, at least as far as the chick is concerned, the validity of this hypothesis remains questionable because in the same study indomethacin, inhibitor of COX [13] , had no effect on FDM, suggesting that endogenous prostaglandins are unlikely to play a significant role in the development of FDM. One alternative that could possibly explain this negative effect of indomethacin on FDM is that the reported isoprostane pathway is an alternative route not involving COX, which also generates PGF2a in humans [14] . Therefore, changes in PGF2a levels could occur despite lack of inhibition of axial length extension by indomethacin in chicks. Another possible explanation for this negative effect is that there are species-specific variations in drug concentration and delivery routes required to affect a change in PGF2a levels. Therefore, despite these uncertainties, we felt justified in determining whether PGF2a receptor (FP) FP receptor modulations affect emmetropization and/or FDM progression in guinea pigs.
The FP receptor is widely expressed in all of the ocular tissues as well as connective tissue fibroblasts and has essential roles in controlling inflammation, pain modulation, allergies besides affecting intraocular pressure (IOP) in a variety of different species [15] . Latanoprost, an isopropyl ester substituent replacing the a-carboxylic acid, has been approved for use as an ocular hypotensive drug. Its active form in vivo latanoprost acid (LAT, the free acid form) is 200-fold more potent at the FP receptor [16] . The half maximal effective concentration (EC 50 ) of LAT is 3.6 nM for human FP receptors, twice that of PGF2a. AL8810 is an 11b-fluoro analogue of PGF2a which acts as a potent and selective FP receptor antagonist. Its inhibition constant (K i ) for the inhibition of several potent agonists at the cloned human ciliary body FP receptor is in the range of 1-2 lM [17] .
As PGF2a is an endogenous selective FP agonist, in this study we quantified levels of retinal PGF2a after exposure to FD and evaluated whether FP receptor modulation affects emmetropization and myopia progression using LAT and AL8810 in guinea pigs.
Methods
Animals. The animal usage protocol was approved by the Animal Care and Ethics Committee at Wenzhou Medical University, Wenzhou, China, according to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Two-week-old wild-type pigmented guinea pigs (Cavia porcellus, the English short hair stock, tricolour strain) were obtained from the animal laboratory centre of Zhejiang University in Hangzhou, China. A total of 160 animals (irrespective of gender) were randomly assigned to normal vision and monocular FD groups, among which 24 were used for retinal PGF2a quantification while 136 for emmetropization or FDM evaluation (table 1). All of the animals were reared every day under a 12-hr light/12-hr dark cycle (lights on at 8:00 AM) in their housing facilities with room temperature maintained at 25°C. Illuminance at the cage floor was approximately 300 lux, provided by incandescent bulbs. The animals had free access to standard food and water with fresh vegetables provided twice a day.
Establishment of form deprivation. Monocular visual disruption was induced in guinea pigs with a facemask made of latex balloons covering their right eye while leaving the left eye, nose, mouth and ears uncovered (Suzhou, China) [10] . The facemask was examined for its integrity and correct placement thrice a week. It was replaced with a new one of suitable size, if necessary. The facemask was only temporarily removed during drug injection in a room under dim red light.
Biometric measurements. Biometric parameters, including refraction, anterior chamber depth (ACD), lens thickness (LT), vitreous chamber depth (VCD), axial length (AL) and IOP, were measured in all animals at baseline and again 2 and 4 weeks after the experiment started. These measurements were performed by an optometrist, who was masked with regard to the identity of the treatment group.
Refraction of the eyes was measured based on the pupil vertical meridian using an eccentric infrared photorefractor [18] . Guinea pigs were amenable to being readily aligned towards the camera without general anaesthesia, resulting in a clear pupillary reflex. Illumination of the examination room was dimmed to approximately 5 lux. Three readings of the refractive measurements were recorded with the mean used for statistical analysis.
Axial components of the eye (i.e. ACD, LT, VCD and AL) were measured in unanaesthetized animals with A-scan ultrasonography (AVISO Echograph Class I-Type Bat; Quantel Medical, Clermont-Ferrand, France) on the same day following refraction measurements [19] . The cornea was topically anaesthetized with a drop of 0.5% proparacaine hydrochloride (Alcon, Puurs, Belgium). Each parameter was measured at least 8 times with their mean values used for analysis.
Intraocular pressure (IOP) was recorded with TonoVet TV01 Tonometer (TioLat, Helsinki, Finland) after axial components measurements. Three measurements were obtained from each eye, and the mean value was used for statistical analysis.
All biometric parameters were measured prior to any treatment and subsequently at 2 and 4 weeks after treatment. In animals undergoing FD, the facemask was taken off one minute before a measurement and replaced immediately after each measurement.
Retinal PGF2a quantification. Twenty-four guinea pigs (10 in control group, 14 in FD group) were immediately killed after biometric measurements via cervical dislocation after 2 weeks of FD. The right eye of each animal was enucleated and placed on an inverted ice-cold culture dish for dissection of the cornea, lens and the optic nerve head, leaving an eyecup. The entire retina with all its layers was carefully isolated from the eyecup. Retinas were weighed and frozen in liquid nitrogen followed by storage at À80°C prior to measurement.
On the day of measurement, samples were thawed at room temperature and homogenized in 100 lL methanol for 2 min. The samples were centrifuged at 12,000 9 g for 10 min. under 4°C. A total of 50 lL of aqueous supernatant was transferred to a LC vial. The separation and detection of PGF2alpha were performed on a Waters Acquity ultraperformance liquid chromatography system (UPLC) coupled with a Waters Xevo TQ MS triple quadrupole mass spectrometer. Separation was achieved on an Acquity BEH C18 column (2.1 mm by 100 mm; 1.7-lm particle size). A gradient elution programme was conducted for chromatographic separation with mobile phase A (10 mM ammonium acetate in water) and mobile phase B ( The mass spectrometer was operated using an electrospray source in negative mode. The PGF2a MRM transitions were m/z 353.1?m/z 193.0. The system control and data analysis were carried out using Analyst 1.5.2 data processing program.
Pharmacological manipulation. The selective FP receptor agonist, LAT, and antagonist, AL8810, were purchased from Sigma-Aldrich (St. Louis, MO, USA). They were dissolved in dimethyl sulphoxide (DMSO, Sigma-Aldrich) and then diluted in Milli-Q water to the final DMSO working concentration of 0.1%. Animals in vehicle control groups were injected with 100 lL of solvent, that is Milli-Q water containing 0.1% DMSO, into the peribulbar space of the right eye without anaesthesia, using a 0.45 9 16-mm syringe cannula attached to a 25-gauge needle. Each animal in the drug-treated groups was injected with 100 lL of vehicle containing designated drug doses (table 1). All injections were conducted under dim red light once daily (at 9:00 AM). The left eyes of all animals remained untreated throughout the experiment. In animals experiencing FD, the facemask was taken off a few seconds before the injection and was replaced immediately after each measurement. FD and drug treatment were carried out for 4 weeks.
Statistical analysis. All data are expressed as the mean AE standard error of mean (S.E.M.). All measured ocular parameters for right and left eyes were compared using paired t-test. To identify treatment effects among the different groups, interocular differences (differences between treated and fellow eyes) were calculated for refractive status and axial components. Two-way ANOVA with repeated measures followed by Bonferroni post hoc analysis was performed to compare vehicle groups with control groups and drug-treated groups. All statistical analysis was performed using SPSS (Version 16.0). A p value of less than 0.05 was considered as being significant. A post hoc power analysis was conducted to evaluate the experiment design in determining drug effects on emmetropization and FDM with the program G*Power [20] .
Results
Baseline refraction and axial component measurements were not different between the right and left eyes of individual animals in each subgroup (p > 0.05, paired t-test). Furthermore, the refraction and axial component values in the left untreated eyes after 2 and 4 weeks were similar to those previously described [11] . These results show that wild-type guinea pigs undergo emmetropization in an unobstructed vision environment.
Retinal PGF2a declined after form deprivation. The refraction of right eyes in the normal control group was 4.6 AE 0.82 D, while after 2 weeks of FD, it was 1.45 AE 2.43 D. The difference between these two groups was statistically significant (p < 0.001, two-sample independent t-test). Retinal PGF2a levels in the normal eyes were 14.24 pg/mg, while in the FD eyes, it declined to 9.92 pg/mg which was statistically significant (p < 0.01, two-sample independent t-test, fig. 1 ).
IOP unchanged by either LAN or AL8810. The IOP of the 2-week-old guinea pigs was averagely 11.7 AE 0.42 mmHg. There was no significant difference between IOP of left and right eyes during 4 weeks exposure to either a normal (table 2) or a vision obstructed environment  (table 3) , irrespective of DMSO, LAT acid or AL8810 injected into the right eyes (paired t-test, p > 0.05).
FP receptor agonism had no effect on emmetropization while antagonism induced myopia. the two groups throughout the 4 weeks of treatment, although there seemed to be a slight time-dependent myopic trend in the interocular difference ( fig. 2A) . Two-way ANOVA revealed no statistical significance between DMSO-and LAT-injected eyes (p > 0.05). This result is consistent with slight but insignificant changes in interocular differences in VCD and AL ( fig. 2B,C) . LAT treatment did not change the interocular ACD and AL differences (table 2). To determine whether the non-significant results were caused by a lack of statistical power, we conducted post hoc power analysis with power set at 0.80 and a = 0.05, two-tailed. In order for group interocular differences in refraction, VCD and AL to reach statistical significance at the 0.05 level, the sample sizes would have had to increase up to N = 104, 742 and 92, respectively. Thus, it is unlikely that these negative findings can be attributed to a limited sample size. Monocular FD of the right eyes injected with DMSO induced a myopia of À3.57 AE 0.41 and À7.53 AE 0.50 D after 2 and 4 weeks, respectively. On the other hand, FD eyes injected with 0.5 lg AL8810 developed a myopia of À4.33 AE 0.77 and À8.07 AE 1.17 D at these corresponding time-points. The interocular difference in refraction was significantly larger than that caused by DMSO (F 1,27 = 22.39, p < 0.001, fig. 2D ). Daily injections of AL8810 induced significant myopia of À0.76 AE 0.22 D at 2 weeks and À1.99 AE 0.34 D after 4 weeks of treatment. This shift in refraction was accompanied by increases in VCD and AL elongation ( fig. 2E,F) . There was no significant change in interocular differences in ACD and LT after AL8810 treatment (table 2) . With obtained standard deviation from current samples, the achieved power to reject the hypothesis that there are no significant differences between the effects of DMSO and AL8810 on interocular differences in refraction, VCD and AL was 0.933, 0.566 and 0.401, respectively. The lower power in VCD and AL is attributed to a relatively larger standard deviation because of small eye size in guinea pigs.
FP receptor agonism inhibited FDM, whereas its antagonism had no effect. fig. 3B,C) . Interocular differences in ACD and LT were not significantly changed post-LAT treatment (table 3) . With obtained standard deviation from current sample size, the achieved power to reject the hypothesis that there are no significant differences between effects of DMSO and AL8810 in interocular differences in refraction, VCD and AL was 0.738, 0.587 and 0.653, respectively. The lower power in VCD and AL is attributed to a relatively larger standard deviation attributable to the small eye size in guinea pigs. Form deprivation eyes injected with 0.5 lg AL8810 developed a myopia of À4.33 AE 0.78 and À8.07 AE 1.17 D after 2 and 4 weeks of treatment. While in the accompanying vehicle Fig. 2 . During emmetropization, only FP antagonism induced myopia, while agonism had no effect. (A-C) Changes in interocular difference in refraction, VCD and AL in response to LAT. (D-F) Changes in interocular difference in refraction, VCD and AL in response to AL8810. DMSO: milli-Q water containing 1% DMSO as vehicle control; N: sample number. Dosages of LAT and AL8810 are shown in parentheses. # denotes significance of difference between AL8810-and DMSO-injected eyes revealed by two-way ANOVA (#p < 0.05; ##p < 0.01; ###p < 0.001). *Significance of difference between AL8810-and DMSO-injected eyes at a specific time-point (**p < 0.01; ***p < 0.001).
control group, FD eyes injected with DMSO presented with a myopia of À3.57 AE 0.41 and À7.53 AE 0.50 D after 2 and 4 weeks of treatment. AL8810 did not induce any significant interocular differences in refraction and ocular biometric parameters compared with the DMSO-treated group ( fig. 3, table 3 ). The post hoc power analysis (power set at 0.80 and a = 0.05, two-tailed) showed that sample sizes of up to N = 382, 2120 and 704 are required to reach statistical differences between DMSO and 0.5 lg AL8810 in interocular differences in refraction, VCD and AL at the 0.05 level. Thus, it is unlikely that these negative findings are due to a limited sample size.
Discussion
We show here that retinal PGF2a declined in form-deprived retina, inhibition of PGF2a-FP receptor signalling pathway by AL8810 induced a refractive shift to myopia during emmetropization while up-regulation of this pathway by LAT inhibited FDM progression in guinea pigs. The opposing effects of LAT and AL8810 are supportive of our hypothesis that blunted FP receptor activity contributes to FDM as a result of declines in retinal PGF2a level and likely down-regulation of its linked signalling pathway. There is some not entirely consistent evidence that FP receptor modulation affects changes in myopia progression in form-deprived chick eyes. Jin et al. reported that intravitreal injection of the endogenous FP receptor agonist, PGF2a, significantly reduced FD-induced axial elongation. Similarly, we found that LAT injected into the peribulbar space significantly reduced FD-induced axial elongation. On the other hand, neither PGF2a nor LAT suppressed myopia development subsequent to being delivered either as eyedrops or by subconjunctival injection [8] . It is conceivable that the negative effects of LAT in chicks are attributable to insufficient LAT tissue permeation via the ocular surface or through subconjunctival injection. Limited LAT penetrance could be a factor because the active LAT form, which we and Jin et al. used, was reportedly less effective in lowering IOP than its prodrug form in human glaucoma patients [21] . If LAT penetrance is more limiting across the aforementioned routes in the chick, then it is via the peribublar path in guinea pigs, and such a difference may explain why LAT failed to inhibit FDinduced axial elongation in chicks. As drug effects are known not to be consistent on myopia progression between different species, it is also possible that FP involvement in controlling myopia development is not the same in the chicks and guinea pigs.
Latanoprost is one of the four commercially available prostanoids for glaucoma treatment, the other three being tafluprost, travoprost and bimatopros. LAT is the active form of latanoprost, which reduces IOP through short-and long-term increases in aqueous out-flow in humans [15] . Over the shortterm, latanoprost eye drop application to the ocular surface transiently and maximally decreased IOP by 30-40% with a time delay of up to 8-12 hr [15] . Its IOP reducing effect is attributed to a relaxation of smooth muscle tissue, which caused a quick transient decrease in IOP that was restored to normal after treatment was stopped. On the other hand, longterm repeated latanoprost treatment had a long-lasting IOPlowering effect which persisted after treatment was stopped. This hypotensive effect presumably occurs as a consequence of ciliary body and/or sclera extracellular remodelling that reduces scleral stiffness and biomechanical strength in humans [22] [23] [24] . The commonly used latanoprost dose in experimental models to characterize its IOP-lowering effects is 0.005%, that is, 4.5 lg LAT in 100 lL if fully catalysed by COX. However, we found that 30 lg LAT contained in a 100 lL solution inhibited myopia progression but without reducing IOP during 4 weeks of treatment. The failure to observe a longlasting effect of LAT on IOP is consistent with another report in which 0.005% LAT rapidly and temporarily decreased IOP for only one hour in guinea pigs without any long-lasting effect [25] . As we measured the IOP approximately 22 hr after the last LAT injection, it is possible that we missed the transient decline in IOP observed in the aforementioned study. This difference between the effects of LAT shows that it is not possible to translate the IOP-lowering effects of LAT from one species to another. For example, LAT is even reported to have instead a hypertensive effect due to rupture of the bloodaqueous barrier [26] . These considerations make it unlikely that our failure to identify an IOP-lowering effect by LAT is attributable to experimental error.
There is abundant evidence showing that myopia development results from excessive optic axial elongation, which is accommodated by declines in scleral stiffness and biomechanical strength. These scleral changes include losses in collagen expression, increases in collagen turnover, myofibrobalst transdifferentiation and matrix metalloproteinase (MMP) up-regulation as well as extracellular matrix remodelling [2] . Such changes also account for how LAT increases non-conventional uveoscleral out-flow. In addition, LAT increased matrix MMP activity and reduced levels of MMP tissue inhibitors (TIMP) which are endogenous inhibitors of this enzymatic activity [27, 28] . On the other hand, the declines in FDM and biometric parameters changes induced by LAT are inconsistent with the scleral weakening and loss of stiffness associated with increases in uveoscleral out-flow induced by this drug. Nevertheless, these effects of LAT on FDM agree with the inhibitory effect of intravitreal PGF2a injection on myopia progression even though LAT had no effect in chicks. Finally, resolution of this conundrum regarding how LAT only decreases FDM without changing the IOP awaits clarifying the scleral molecular changes induced by this drug in guinea pigs.
Taken together, these results are indicative of retinal FP receptor involvement in controlling myopia progression as in a normal vision environment, the FP antagonist, AL8810, induced a time-dependent shift of eye development to myopia, whereas LAT, the selective FP agonist, inhibited FDM progression. A possible explanation for these effects is that during emmetropization, retinal FP receptor-linked signalling is highly activated causing LAT to be ineffective under this condition. On the other hand, during FDM, FP receptor activation is not maximal due to a presumed decline in PF2a levels. Under this condition, LAT is effective as a consequence of increasing FP receptor activity.
